Closing arguments in the first trial of Philadelphia's Risperdal mass-tort actions focused largely on attacking the testimony and backgrounds of the experts.

Plaintiffs attorney Thomas R. Kline of Kline & Specter referenced a defense expert who came from Alabama as “Dr. Alabama,” and argued the doctor was less qualified than Kline's experts. However, during the defense's portion of the arguments, counsel for Janssen Pharmaceuticals, the defendant in the case, referred to the plaintiff's experts as “regulars on the litigation circuit.”

The arguments, which were heard Feb. 20, came after nearly a month of trial over whether the drugmaker failed to warn patients about the risk of gynecomastia, a condition in which young males grow breast tissue.